Investors watching for signs of M&A activity from Gilead Sciences Inc. could be eyeing the big biotech even more closely after top-line phase II data revealed a missed primary endpoint for HBV contender GS-4774, prompting speculation that the firm could tap other players to shore up its early but promising HBV pipeline. more »
HONG KONG – After eyeing biopharmaceuticals as a key area for breakthrough developments, China's State Council has released a roadmap for the manufacturing sector. "Made in China 2025" is a plan to boost the capacity of the country's manufacturing over the next decade.more »
Researchers at Boston Children's Hospital have used a novel type of screening to identify a compound that caused massive weight loss in mice with diet-induced obesity, causing them to lose 45 percent of their body weight. more »
In a self-declared "love fest," the House Energy and Commerce Committee put aside partisan politics Thursday, voting 51-0 to pass the 21st Century Cures Act, H.R. 6, in the hope of streamlining the process of developing and approving new medical treatments. more »
- CAR-T wheels 'n' deals: Juno, Editas gene-editing pact in $737M-plus range
- HBV candidate falters in phase II; Gilead to seek other options?
- Streamlining efforts or propaganda? ALBA unveils regulatory center
- Reduced blood-brain barrier transport spells trouble in Alzheimer's
- Twin tragedies teach medical countermeasures les...
- China channels resources to expand biopharma sector in 10-year plan
- China’s center for drug evaluation triples staff; 50 to 190, officially
- Takeda, Japan’s NCC in drugs, diagnostics effort against cancer
- China’s drug price cap removal likely to benefit larger pharmas: analyst
- Chinese consortium snaps up Ambrx to bring new d...
The release of the American Society of Clinical Oncology (ASCO) annual meeting abstracts has become almost as much of an anticipated event by Wall Street, analysts, media and the biopharmaceutical industry as the meeting itself, which this year runs May 29-June 2 in Chicago.
A genomics-based search for better drug targets for painkillers has turned up a candidate that is, in one sense, not new at all.
That candidate is the nicotinic acetylcholine receptor, already the beneficiary of one failed round of drug development.
But the new study, which was published in the May 13, 2015, issue of Science Translational Medicine, suggests that targeting a different subunit of the receptor, and doing so in the periphery, may yield better clinical results.READ MORE »
- Reduced blood-brain barrier transport spells trouble in Alzheimer's »
- WGS helps those sequenced, and possibly others, get a diagnosis »
- Engineered phages can kill antibiotic resistance genes »
- CRISPR surgical strikes aid cancer target discovery »
- New blood pressure finding could lead to new treatments »
- GTEx data look at tissue differences in genome's effects »
- Astrocytes lock down neurons in RASopathies »
- Chinese-U.S. study provides clues to treating aging disorders »
- Novel brown fat regulation target identified in Singapore »
- A world of intrigue, from Missoula to Mars: BioWorld’s 9th Annual Summer Reading ListMay 26, 2015 | 6:31 PM | Posted by: Marie Powers
- You’ve come a long way, baby, but still a long way to goMay 04, 2015 | 2:44 PM | Posted by: Mari Serebrov
- As researchers unlock the brain’s mysteries, let’s not overlook the real questionsApril 27, 2015 | 4:35 PM | Posted by: Marie Powers
- Talk to your doctor: How even annoying DTC ads can contribute to patient communication April 15, 2015 | 4:48 PM | Posted by: Jennifer Boggs
- Sharing deeply of ourselves: Still messyMarch 27, 2015 | 11:17 PM | Posted by: Michael Fitzhugh
Partners in Focus
Cast Your Vote
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter